Claims for Patent: 11,590,204

Summary for Patent: 11,590,204

Title:	Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Abstract:	The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
Inventor(s):	Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
Assignee:	Biomarin Pharmaceutical Inc
Application Number:	US16/837,910
Patent Claims:	1. A formulation comprising: (a) a C-type natriuretic peptide (CNP) variant selected from the group consisting of [CNP-37(M32N); SEQ ID NO: 1] QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC; (Met-CNP-37; SEQ ID NO: 2) MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; (Pro-CNP-37; SEQ ID NO: 3) PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; [Gly-CNP 37(M32N); SEQ ID NO: 4] GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC; (Pro-Gly-CNP-37; SEQ ID NO: 5) PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; (Met-Gly-CNP-37; SEQ ID NO: 6) MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; and (Gly-CNP-37: SEQ ID NO: 7) GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; and (b) citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, D-mannitol, L-methionine and polysorbate 80, wherein the formulation comprises less than 2.0 mg/ml of said CNP peptide variant. 2. The formulation of claim 1 that is lyophilized. 3. The formulation of claim 1 that is in liquid form or reconstituted from a lyophilized formulation. 4. The formulation of claim 1, wherein said citric acid monohydrate is present at a concentration of from about 0.15 mg/ml to about 0.40 mg/ml, said sodium citrate dihydrate is present at a concentration of from about 0.5 mg/ml to about 1.5 mg/ml, said trehalose dihydrate is present at a concentration of from about 30 mg/ml to about 70 mg/ml, said D-mannitol is present at a concentration of from about 10 mg/ml to about 20 mg/ml, said L-methionine is present at a concentration of from about 0.5 mg/ml to about 1.5 mg/ml and said polysorbate 80 is present at a concentration of from about 0.01 mg/ml to about 0.1 mg/ml. 5. The formulation of claim 1, wherein said citric acid monohydrate is present at a concentration of about 0.28 mg/ml, said sodium citrate dihydrate is present at a concentration of about 1.08 mg/ml, said trehalose dihydrate is present at a concentration of about 58.01 mg/ml, said D-mannitol is present at a concentration of about 15 mg/ml, said L-methionine is present at a concentration of about 0.73 mg/ml and said polysorbate 80 is present at a concentration of about 0.05 mg/ml. 6. The formulation of claim 1 which is preservative-free. 7. The formulation of claim 1 having a pH of between about 5.0 and about 6.0. 8. A formulation comprising: (a) a C-type natriuretic peptide (CNP) variant selected from the group consisting of [CNP-37(M32N); SEQ ID NO: 1] QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC; (Met-CNP-37; SEQ ID NO: 2) MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; (Pro-CNP-37; SEQ ID NO: 3) PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; [Gly-CNP 37(M32N); SEQ ID NO: 4] GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC; (Pro-Gly-CNP-37; SEQ ID NO: 5) PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; (Met-Gly-CNP-37; SEQ ID NO: 6) MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; and (Gly-CNP-37: SEQ ID NO: 7) GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; and (b) citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, D-mannitol, L-methionine and polysorbate 80, wherein the formulation comprises about 0.5 to about 2.0 mg/ml of said CNP peptide variant. 9. The formulation of claim 8 that is lyophilized. 10. The formulation of claim 8 that is in liquid form or reconstituted from a lyophilized formulation. 11. The formulation of claim 8, wherein said citric acid monohydrate is present at a concentration of from about 0.15 mg/ml to about 0.40 mg/ml, said sodium citrate dihydrate is present at a concentration of from about 0.5 mg/ml to about 1.5 mg/ml, said trehalose dihydrate is present at a concentration of from about 30 mg/ml to about 70 mg/ml, said D-mannitol is present at a concentration of from about 10 mg/ml to about 20 mg/ml, said L-methionine is present at a concentration of from about 0.5 mg/ml to about 1.5 mg/ml and said polysorbate 80 is present at a concentration of from about 0.01 mg/ml to about 0.1 mg/ml. 12. The formulation of claim 8, wherein said citric acid monohydrate is present at a concentration of about 0.28 mg/ml, said sodium citrate dihydrate is present at a concentration of about 1.08 mg/ml, said trehalose dihydrate is present at a concentration of about 58.01 mg/ml, said D-mannitol is present at a concentration of about 15 mg/ml, said L-methionine is present at a concentration of about 0.73 mg/ml and said polysorbate 80 is present at a concentration of about 0.05 mg/ml. 13. The formulation of claim 8 which is preservative-free. 14. The formulation of claim 8 having a pH of between about 5.0 and about 6.0. 15. A formulation comprising: (a) a C-type natriuretic peptide (CNP) variant selected from the group consisting of [CNP-37(M32N); SEQ ID NO: 1] QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC; (Met-CNP-37; SEQ ID NO: 2) MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; (Pro-CNP-37; SEQ ID NO: 3) PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; [Gly-CNP 37(M32N); SEQ ID NO: 4] GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC; (Pro-Gly-CNP-37; SEQ ID NO: 5) PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; (Met-Gly-CNP-37; SEQ ID NO: 6) MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; and (Gly-CNP-37: SEQ ID NO: 7) GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC; and (b) citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, D-mannitol, L-methionine and polysorbate 80, wherein the formulation comprises 10.0 mg/ml±9.9 mg/ml of said CNP peptide variant. 16. The formulation of claim 15 comprising about 0.8 mg/ml of said CNP variant. 17. The formulation of claim 15 that is lyophilized. 18. The formulation of claim 15 that is in liquid form or reconstituted from a lyophilized formulation. 19. The formulation of claim 15, wherein said citric acid monohydrate is present at a concentration of from about 0.15 mg/ml to about 0.40 mg/ml, said sodium citrate dihydrate is present at a concentration of from about 0.5 mg/ml to about 1.5 mg/ml, said trehalose dihydrate is present at a concentration of from about 30 mg/ml to about 70 mg/ml, said D-mannitol is present at a concentration of from about 10 mg/ml to about 20 mg/ml, said L-methionine is present at a concentration of from about 0.5 mg/ml to about 1.5 mg/ml and said polysorbate 80 is present at a concentration of from about 0.01 mg/ml to about 0.1 mg/ml. 20. The formulation of claim 15, wherein said citric acid monohydrate is present at a concentration of about 0.28 mg/ml, said sodium citrate dihydrate is present at a concentration of about 1.08 mg/ml, said trehalose dihydrate is present at a concentration of about 58.01 mg/ml, said D-mannitol is present at a concentration of about 15 mg/ml, said L-methionine is present at a concentration of about 0.73 mg/ml and said polysorbate 80 is present at a concentration of about 0.05 mg/ml. 21. The formulation of claim 15 which is preservative-free. 22. The formulation of claim 15 having a pH of between about 5.0 and about 6.0. 23. A method of treating skeletal dysplasia in a subject in need thereof comprising the step of administering to said subject a formulation of claim 1, wherein the step of administering treats said skeletal dysplasia. 24. The method of claim 23, wherein the treatment results in an improvement in one or more symptoms of skeletal dysplasia selected from the group consisting of increased absolute growth, increased growth velocity, increased quantitative computed tomography (QCT) bone mineral density (BMD), improvement in growth plate morphology, increased long-bone growth, improvement in morphology of the spine, improved elbow joint range of motion and decreased sleep apnea. 25. The method of claim 23, wherein the skeletal dysplasia is selected from the group consisting of achondroplasia, hypochondroplasia, short stature, dwarfism, osteochondrodysplasias, thanatophoric dysplasia, osteogenesis imperfecta, achondrogenesis, chondrodysplasia punctata, homozygous achondroplasia, campomelic dysplasia, congenital lethal hypophosphatasia, perinatal lethal type of osteogenesis imperfecta, short-rib polydactyly syndromes, rhizomelic type of chondrodysplasia punctata, Jansen-type metaphyseal dysplasia, spondyloepiphyseal dysplasia congenita, atelosteogenesis, diastrophic dysplasia, congenital short femur, Langer-type mesomelic dysplasia, Nievergelt-type mesomelic dysplasia, Robinow syndrome, Reinhardt syndrome, acrodysostosis, peripheral dysostosis, Kniest dysplasia, fibrochondrogenesis, Roberts syndrome, acromesomelic dysplasia, micromelia, Morquio syndrome, Kniest syndrome, metatrophic dysplasia, and spondyloepimetaphyseal dysplasia. 26. The method of claim 23, wherein said composition is administered once daily. 27. The method of claim 26, wherein said formulation is administered once daily over a period of at least 6 months. 28. The method of claim 23, wherein said formulation is administered subcutaneously. 29. The method of claim 23 comprising administering said formulation comprising said CNP variant to said subject at a dose of at least about 7.5 μg/kg per day to about 60 μg/kg per day of said CNP variant. 30. The method of claim 29, wherein the formulation comprising said CNP variant is administered to said subject at a dose of about 15 μg/kg per day of said CNP variant. 31. The method of claim 29, wherein the formulation comprising said CNP variant is administered to said subject at a dose of 15 μg/kg per day of said CNP variant peptide. 32. A method of increasing long bone growth in a subject in need thereof comprising the step of administering to said subject a formulation of claim 1, wherein the step of administering increases long bone growth in said subject. 33. A method of increasing growth velocity in a subject in need thereof comprising the step of administering to said subject a formulation of claim 1, wherein the step of administering increases growth velocity in said subject, wherein growth velocity is measured as a change in standing height, sitting height, head circumference, upper arm length, lower arm length, upper leg length, lower leg length, hand length or foot length.